AbbVie: Rinvoq And Skyrizi Will Bridge US Humira Sales Erosion Through 2025
Executive Summary
Continuing its longstanding effort to assure investors about growth past Humira’s US patent expiry in 2023, the pharma outlined label-expansion and market share plans for its two newer immunology drugs.
You may also be interested in...
AbbVie Ups Its IBD Game With Latest Crohn’s Data For Rinvoq
The leader in inflammatory bowel disease via Humira, AbbVie awaits a US FDA decision in June for Skyrizi in Crohn’s disease and plans to add a Crohn’s indication to Rinvoq’s ulcerative colitis approval.
AbbVie Focuses On Humira’s Formulary Positioning Ahead Of Biosimilars
A year out from the US patent expiration for top-seller Humira, AbbVie is negotiating for formulary position alongside biosimilars. Analysts said success there could delay some patent cliff pain until 2024.
AbbVie Remains Confident About Rinvoq Despite Coming Safety Labeling Update
A safety-related FDA revision of Rinvoq’s label in rheumatoid arthritis is a perceived threat to the JAK inhibitor’s growth, but it and fellow immunology asset Skyrizi produced another strong sales quarter.